These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 19606178

  • 1. Orbital inflammation and optic neuropathy with zoledronic acid for metastatic prostate cancer.
    Seth A, Anderson DP, Albiani DA, Barton JJ.
    Can J Ophthalmol; 2009 Aug; 44(4):467-8. PubMed ID: 19606178
    [No Abstract] [Full Text] [Related]

  • 2. Orbital inflammatory disease after intravenous infusion of zoledronate for treatment of metastatic renal cell carcinoma.
    Phillips PM, Newman SA.
    Arch Ophthalmol; 2008 Jan; 126(1):137-9. PubMed ID: 18195236
    [No Abstract] [Full Text] [Related]

  • 3. Nitrogen bisphosphonate-induced orbital inflammatory disease: gamma delta T cells--a report and review of 2 cases.
    Vora MM, Rodgers IR, Uretsky S.
    Ophthalmic Plast Reconstr Surg; 2014 Jan; 30(4):e84-5. PubMed ID: 24814269
    [Abstract] [Full Text] [Related]

  • 4. Orbital Inflammation Secondary to Zoledronic Acid, a Rare Presentation.
    Muruganandam M, Sandhu H.
    J Clin Rheumatol; 2016 Oct; 22(7):384. PubMed ID: 27488454
    [No Abstract] [Full Text] [Related]

  • 5. Orbital inflammation after use of zoledronic acid for metastasized prostate carcinoma.
    Missotten G, Verheezen Y.
    Bull Soc Belge Ophtalmol; 2010 Oct; (315):23-4. PubMed ID: 21110506
    [Abstract] [Full Text] [Related]

  • 6. Orbital inflammatory disease after pamidronate treatment for metastatic prostate cancer.
    Subramanian PS, Kerrison JB, Calvert PC, Miller NR.
    Arch Ophthalmol; 2003 Sep; 121(9):1335-6. PubMed ID: 12963622
    [No Abstract] [Full Text] [Related]

  • 7. A Case Series and Review of Bisphosphonate-associated Orbital Inflammation.
    Lefebvre DR, Mandeville JT, Yonekawa Y, Arroyo JG, Torun N, Freitag SK.
    Ocul Immunol Inflamm; 2016 Sep; 24(2):134-9. PubMed ID: 25153041
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA.
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [Abstract] [Full Text] [Related]

  • 16. Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.
    Gulley JL, Wu S, Arlen PM, Dahut WL.
    Clin Genitourin Cancer; 2007 Sep; 5(6):403-5. PubMed ID: 17956715
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.